RO.SW : Summary for ROCHE I - Yahoo Finance

U.S. Markets close in 1 hr 7 mins

Roche Holding AG (RO.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
254.75+1.75 (+0.69%)
At close: 5:31PM CEST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close253.00
Bid254.00 x
Ask255.50 x
Day's Range253.50 - 255.50
52 Week Range221.80 - 265.50
Avg. Volume26,796
Market Cap217.11B
PE Ratio (TTM)22.88
Earnings DateN/A
Dividend & Yield8.22 (3.24%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire3 hours ago

    FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

    Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted unanimously that the benefit-risk of rituximab/hyaluronidase for subcutaneous injection was favorable for the treatment of certain blood cancers, which include: previously untreated follicular lymphoma, previously untreated diffuse large B-cell lymphoma , relapsed ...

  • Reuters9 hours ago

    UPDATE 2-Roche MS drug Ocrevus approved by FDA after 3-month delay

    The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues. The infusible drug, known chemically as ocrelizumab, becomes the first U.S.-approved medicine for the primary progressive form of the neurological disease (PPMS). It is also approved to treat the most common form of the disease, known as relapsing-remitting multiple sclerosis (RRMS).

  • Business Wire18 hours ago

    FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis

    Genentech, a member of the Roche Group , announced today that the U.S. Food and Drug Administration approved OCREVUS™ as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis.